Kodiak Sciences Inc (KOD)

NASDAQ
Currency in USD
3.535
-0.525(-12.93%)
Closed·
After Hours
3.700+0.165(+4.668%)
·
KOD Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
KOD is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.4404.030
52 wk Range
1.92011.600
Key Statistics
Edit
Prev. Close
4.06
Open
3.96
Day's Range
3.44-4.03
52 wk Range
1.92-11.6
Volume
571.2K
Average Volume (3m)
427.25K
1-Year Change
24.54%
Book Value / Share
2.07
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KOD Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
6.800
Upside
+92.36%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash
Show more

Kodiak Sciences Inc Company Profile

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company’s preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.

Kodiak Sciences Inc SWOT Analysis


Pipeline Progress
Explore Kodiak's advancing clinical trials, including Phase 3 studies for wet AMD and diabetic retinopathy, with key data expected in 2025-2026.
Financial Crossroads
Kodiak faces financial challenges with negative EPS projections, yet maintains a strong cash position and healthy current ratio of 8.42.
Leadership Overhaul
Delve into the impact of Kodiak's new executive team, appointed in Q2 2024, on the company's strategic direction and operational efficiency.
Market Valuation
Analyst price targets range from $3 to $4, reflecting cautious outlook. Average target of $3.25 suggests potential upside from current levels.
Read full SWOT analysis

Compare KOD to Peers and Sector

Metrics to compare
KOD
Peers
Sector
Relationship
P/E Ratio
−1.0x−3.6x−0.5x
PEG Ratio
−0.06−0.010.00
Price/Book
1.7x1.6x2.6x
Price / LTM Sales
-18.2x3.0x
Upside (Analyst Target)
4.4%207.4%52.7%
Fair Value Upside
Unlock2.0%7.6%Unlock

Analyst Ratings

1 Buy
2 Hold
3 Sell
Ratings:
6 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 6.800
(+92.36% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
1.09 / -1.05
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

FAQ

What Is the Kodiak Sciences (KOD) Stock Price Today?

The Kodiak Sciences stock price today is 3.54

What Stock Exchange Does Kodiak Sciences Trade On?

Kodiak Sciences is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Kodiak Sciences?

The stock symbol for Kodiak Sciences is "KOD."

What Is the Kodiak Sciences Market Cap?

As of today, Kodiak Sciences market cap is 188.94M.

What Is Kodiak Sciences's Earnings Per Share (TTM)?

The Kodiak Sciences EPS (TTM) is -3.62.

When Is the Next Kodiak Sciences Earnings Date?

Kodiak Sciences will release its next earnings report on 17 Aug 2025.

From a Technical Analysis Perspective, Is KOD a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Kodiak Sciences Stock Split?

Kodiak Sciences has split 0 times.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.